284462-86-8

Basic information

• Product Name: 2-Pyridinecarboxamide, 4-(4-aminophenoxy)-N,N-dimethyl-
• CAS NO: 284462-86-8
• Molecular Formula: C14H15N3O2
• Molecular Weight: 257.292
• Mol File: 284462-86-8.mol

Chemical Properties

• CAS DataBase Reference: 2-Pyridinecarboxamide, 4-(4-aminophenoxy)-N,N-dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinecarboxamide, 4-(4-aminophenoxy)-N,N-dimethyl-(284462-86-8)
• EPA Substance Registry System: 2-Pyridinecarboxamide, 4-(4-aminophenoxy)-N,N-dimethyl-(284462-86-8)

Safety Data

• Hazardous Substances Data: 284462-86-8(Hazardous Substances Data)

Upstream product

• 284462-37-9 4-(4-aminophenoxy)-N-methylpyridine-2-carboxamide 
• 373-68-2 tetramethylammonium fluoride 
• 114780-06-2 4-chloro-N,N-dimethylpyridine-2-carboxamide 
• 123-30-8 4-amino-phenol 
• 220000-87-3 4-chloro-N-methylpicolinamide 

Downstream Products

• 75919-92-5 1-(4-(4-nitrophenoxy)phenyl)ethanone 
• 284462-54-0 4-(1-oxoisoindolin-5-yloxy)aniline 
• 220000-87-3 4-chloro-N-methylpicolinamide 

Relevant articles and documents

Selective Methylation of Amides, N-Heterocycles, Thiols, and Alcohols with Tetramethylammonium Fluoride

We herein disclose the use of tetramethylammonium fluoride (TMAF) as a direct and selective methylating agent of a variety of amides, indoles, pyrroles, imidazoles, alcohols, and thiols. The method is characterized by operational simplicity, wide scope, and ease of purification. Our computational studies suggest a concerted methylation-deprotonation as the preferred reaction pathway.

SORAFENIB ANALOGS AND USES THEREOF

The present invention provides, inter alia, compounds according to formula I. Also provided are pharmaceutical compositions and kits containing such compounds. Methods for using such compounds, compositions, and kits for treating a subject having system xc-, dysregulation for activating ferroptosis, for inhibiting system xc- in a cell, and for monitoring treatment of a subject having system xc- dysregulation are provided as well.

OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.